REZDIFFRA

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Italy, Lithuania.

Active ingredients

The drug REZDIFFRA contains one active pharmaceutical ingredient (API):

1	Resmetirom UNII RE0V0T1ES0 - RESMETIROM
	Resmetirom is a liver-directed partial agonist for the thyroid hormone receptor beta (THR-β). Stimulation of THR-β in the liver improves mitochondrial function and lipid metabolism, and increases fatty acid β-oxidation, thereby reducing lipotoxic liver fat, inflammation and liver fibrosis. Resmetirom's liver directed THR-β agonism is particularly relevant in the treatment of MASH and leads to minimal off-target activity on THR-α in tissues such as heart and bone.
	Read more about Resmetirom

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REZDIFFRA Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
REZDIFFRA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A05BA11		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05B Liver therapy, lipotropics → A05BA Liver therapy
Discover more medicines within A05BA11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3128475, 3128486, 3128497
FR	Base de données publique des médicaments	61074015, 65877513, 68177605
IT	Agenzia del Farmaco	052489010, 052489022, 052489034
LT	Valstybinė vaistų kontrolės tarnyba	1104511, 1104512, 1104513
US	FDA, National Drug Code	82576-060, 82576-080, 82576-100